Status: Not yet recruiting
The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
The goal of this clinical trial is to test the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors) in acute ischemic stroke patients associated with atherosclerosis by investigating 1. the change in lipid profile compared to baseline results 2. the effects on prognosis of stroke The participants will be given PCSK9 inhibitor right after confirmation of acute ischemic stroke, and the investigators will compare the results to the control group, whom are acute ischemic stroke patients treated with conventional lipid lowering therapy, statin and/or ezetimibe.
Participants needed: 200
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: Sun U. KwonUpdated: Oct 16, 2023Locations: 1
Eligibility criteria
Non-cardioembolic Stroke [+5]
Presence of high-risk factors for cardioembolism [+10]